Citius Oncology annual cash and equivalents
2022
2022
2023
2023
2024
2025
Citius Oncology Cash & Equivalents Growth & History (CTOR)
Citius Oncology's cash and equivalents was $3.9M for fiscal 2025.
View full Citius Oncology company overviewCitius Oncology annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $3.9M | $3.9M | +3504282.14% |
| 2024 | 2024-09-30 | $112 | −$26,411 | −99.58% |
| 2023 · Dec 31 | 2023-12-31 | $32,746 | −$256,429 | −88.68% |
| 2023 · Sep 30 | 2023-09-30 | $26,523 | $26,523 | — |
| 2022 | 2022-12-31 | $289,175 | — | — |
| 2022 | 2022-09-30 | $0 | — | — |
Citius Oncology quarterly cash and equivalents
Q4.22
Q1.23
Q2.23
Q4.23
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $16.6M | $16.6M | +14788922.32% |
| Q2 2026 | 2026-03-31 | $2.6M | $2.6M | +2350466.07% |
| Q1 2026 | 2025-12-31 | $7.3M | $7.3M | +6513695.54% |
| Q4 2025 | 2025-09-30 | $3.9M | $3.9M | +3504282.14% |
| Q3 2025 | 2025-06-30 | $112 | −$149 | −57.09% |
| Q2 2025 | 2025-03-31 | $112 | −$33,218 | −99.66% |
| Q1 2025 | 2024-12-31 | $112 | −$32,634 | −99.66% |
| Q4 2024 | 2024-09-30 | $112 | −$26,411 | −99.58% |
| Q2 2024 | 2024-06-30 | $261 | −$369,834 | −99.93% |
| Q1 2024 | 2024-03-31 | $33,330 | −$87,046 | −72.31% |
| Q4 2023 · Dec 31 | 2023-12-31 | $32,746 | −$256,429 | −88.68% |
| Q4 2023 · Sep 30 | 2023-09-30 | $26,523 | — | — |
| Q2 2023 | 2023-06-30 | $370,095 | — | — |
| Q1 2023 | 2023-03-31 | $120,376 | — | — |
| Q4 2022 | 2022-12-31 | $289,175 | — | — |
Citius Oncology cash and equivalents trends
Between the periods ended 2022-09-30 and 2025-09-30, Citius Oncology's cash and equivalents increased from $0 to $3.9M, a change of $3.9M. The latest reported quarter, Q3 2026, shows $16.6M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Oncology source filings ↗Community posts
Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, ...
